ReviewViruses2018
The Interactions between Host Glycobiology, Bacterial Microbiota, and Viruses in the Gut.
Review in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- The Gut Microbiome in Enteric Viral Infections: Underlying Mechanisms and Therapeutic Approaches.Microorganisms · 2025Review
- Impact of the Microbiota on Viral Infections.Annual review of virology · 2023Review
- Microbiota-induced regulatory T cells associate withFrontiers in microbiology · 2023Article
- Replication of Human Norovirus in Mice after Antibiotic-Mediated Intestinal Bacteria Depletion.International journal of molecular sciences · 2022Article
- Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.Microbiology spectrum · 2022Article
- The Core Human Microbiome: Does It Exist and How Can We Find It? A Critical Review of the Concept.Nutrients · 2022Review
- Perturbation of Alphavirus and Flavivirus Infectivity by Components of the Bacterial Cell Wall.Journal of virology · 2022Article
- Fucosyltransferase 2: A Genetic Risk Factor for Intestinal Diseases.Frontiers in microbiology · 2022Review
- The Role of Host Glycobiology and Gut Microbiota in Rotavirus and Norovirus Infection, an Update.International journal of molecular sciences · 2021Review
- Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses.Viruses · 2021Review
- Review
- Microbiota Depletion Promotes Human Rotavirus Replication in an Adult Mouse Model.Biomedicines · 2021Article
- Review
- Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19.Probiotics and antimicrobial proteins · 2021Review
- Review
- Interaction of Intestinal Bacteria with Human Rotavirus during Infection in Children.International journal of molecular sciences · 2021Article
- Effect of Direct Viral-Bacterial Interactions on the Removal of Norovirus From Lettuce.Frontiers in microbiology · 2021Article
- Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19.Microbial cell factories · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus (RV) and norovirus (NoV) are the major etiological agents of viral acute gastroenteritis worldwide. Host genetic factors, the histo-blood group antigens (HBGA), are associated with RV and NoV susceptibility and recent findings additionally point to HBGA as a factor modulating the intestinal microbial composition. In vitro and in vivo experiments in animal models established that the microbiota enhances RV and NoV infection, uncovering a triangular interplay between RV and NoV, host glycobiology, and the intestinal microbiota that ultimately influences viral infectivity. Studies on the microbiota composition in individuals displaying different RV and NoV susceptibilities allowed the identification of potential bacterial biomarkers, although mechanistic data on the virus-host-microbiota relation are still needed. The identification of the bacterial and HBGA interactions that are exploited by RV and NoV would place the intestinal microbiota as a new target for alternative therapies aimed at preventing and treating viral gastroenteritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.